WASHINGTON and CRANBURY, N.J., Feb. 25, 2013 /PRNewswire/ -- Viropro, Inc. (OTC: VPRO) and Oncobiologics, Inc. announced today the signing of a biosimilar collaboration agreement. Under the agreement, Viropro will have the rights to manufacture six monoclonal antibody products being developed by Oncobiologics for commercialization in more than 70 emerging market countries (excluding China). Viropro will have exclusive commercialization rights to the six biosimilars for Malaysia. In addition, the companies will co-manage Viropro's Penang, Malaysia Alpha Biologics biomanufacturing subsidiary. The alliance will seek regional partners to drive commercialization.
The six biosimilars are generic versions of Humira®, Rituxan®, Avastin®, Herceptin®, Erbitux® and one other non-disclosed biotherapeutic. These biologics are the most popular therapies in the world for their respective cancer and immune-disease indications, representing annual global revenue of more than $40 billion with more than $6 billion in the emerging countries covered by the agreement. The companies project that Viropro commercial and manufacturing royalties have the potential to grow to an annual revenue run rate of $60–$150 million for Viropro within 10 years. The partnership is planning to launch its first product by late 2014.
"The Oncobiologics biosimilars program is a perfect complement to Viropro's biomanufacturing expertise. Their scientific team is comprised of recognized industry veterans and we are impressed by the high quality of the science they are achieving," said Viropro President & CEO Cynthia Ekberg Tsai . "This partnership brings together high-quality molecules developed to FDA and EU regulatory standards integrated with world class
|SOURCE Oncobiologics, Inc.|
Copyright©2012 PR Newswire.
All rights reserved